Antibodies for Drug Discovery and Development

Custom Anti-biotherapeutic
Generation Service

  • Antibodies to your biotherapeutic in 8 weeks
  • Greater than 90% success rates
  • Success with challenging specificities, e.g. antibody drug-target complexes
  • Multiple mono- and bivalent Fab formats with a choice of detection tags
  • Convert to full immunoglobulin with a choice of isotypes
  • Long-term, secure supply from preclinical research through
    to clinical testing

AbD Serotec has developed highly specific, high affinity anti-biotherapeutic antibodies to support preclinical research, clinical trials and patient monitoring for innovator and biosimilar products. We use the HuCAL® recombinant monoclonal antibody library and an improved method of antibody phage display to generate these fully human antibodies in Fab and full immunoglobulin formats.

Select antibodies to your target from our industry-leading range of premade antibodies against marketed blockbuster monoclonal antibody drugs, or commission a custom made antibody against your proprietary biotherapeutic lead
candidate.Special features of our ready-made antibodies and our custom service include:

  • High specificity and sensitivity for optimal PK assay development
  • Specialized antibodies targeting a complex of the drug and target
  • Fully human immunoglobulins as controls for ADA assays
  • Security, consistency and an unlimited supply throughout preclinical and clinical studies

Ready-made Anti-Biotherapeutic Antibodies

Adalimumab HUMIRA®

Adalimumab HUMIRA®

Select from eight neutralizing antibodies and drug-target complex binders for PK and ADA assays

Alemtuzumab Lemtrada®

Alemtuzumab Lemtrada®

Five neutralizing antibodies in Fab or full immunoglobulin format. Affinity range 2.4-0.2 nM

Bevacizumab Avastin®

Bevacizumab Avastin®

Three neutralizing antibodies in Fab or full immunoglobulin format, including HRP conjugated for PK assays

Cetuxumab Erbitux®

Cetuximab Erbitux®

Four neutralizing antibodies and one non-neutralizing for total drug detection. Affinity range 13.5-0.5 nM

Golimumab Simponi®

Golimumab Simponi®

Select from eight neutralizing, non-neutralizing and drug-target complex binding antibodies for PK and ADA assays. Affinity range 85-1.9 nM

Infliximab Remicade®

Infliximab Remicade®

Seven neutralizing and non-neutralizing antibodies in Fab or full immunoglobulin format for PK and ADA assays. Affinity range 3.9-0.1 nM

Rituximab Rituxan®

Natalizumab Tysabri®

Three anti-idiotypic antibodies, for detection of free natalizumab, ideal for ELISA, PK & ADA assays

Omalizumab Xolair®

Omalizumab Xolair®

Select from four neutralizing antibodies and drug-target complex binders for PK and ADA assays. Affinity range 1.1-0.58 nM

Rituximab Rituxan®

Rituximab Rituxan®

Five antibodies suitable for ELISA, PK and ADA assays, including clone MB2A4 with HRP or FITC label for flow cytometry

Rituximab Rituxan®

Tocilizumab Actemra®

Five neutralizing antibodies and one non-neutralizing for total drug detection. Affinity range 31-0.1 nM

Trastuzumab Herceptin®

Trastuzumab Herceptin®

Six neutralizing antibodies in Fab or full immunoglobulin format, suitable for ELISA, PK and ADA assays

Ustekinumab Stelara®

Ustekinumab STELARA®

Four neutralizing antibodies in Fab or full immunoglobulin format, suitable for ELISA, PK and ADA assays

 

Recombinant Fully-Human Immunoglobulin Isotype Controls

Recombinant Fully Human Isotype Controls

Differentiate non-specific background signals from the target-specific antibody signal

  • IgA, IgE, IgG1, IgG2, IgG3, IgG4, IgM
  • Human cell line expressed for human glycosylation pattern
  • Kappa and lambda light chain versions for each isotype